Background: Roflumilast cream is a potent phosphodiesterase 4 inhibitor recently approved in the United States for treatment of plaque psoriasis with no limitations on duration use. An open-label trial was conducted to evaluate long-term safety (52 weeks) once-daily roflumilast (NCT03764475). This abstract presents data durability response as measured by percentage patients an Investigator Glob...

score, air-flow limitation and exercise tolerance) Index: a new composite score for the stratification of severity in chronic obstructive pulmonary disease. Postgrad Med J 2007; 83: 492–497. 13 Cardoso F, Tufanin AT, Colucci M, et al. Replacement of the 6-min walk test with maximal oxygen consumption in the BODE Index applied to patients with COPD: an equivalency study. Chest 2007; 132: 477–482...